⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RYTM News
Rhythm Pharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
RYTM
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
globenewswire.com
RYTM
Form 8-K
sec.gov
RYTM
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
globenewswire.com
RYTM
Form 8-K
sec.gov
RYTM
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
globenewswire.com
RYTM
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
globenewswire.com
RYTM